LIVE WEBINAR
Wednesday, July 15 | 2pm ET
Duration: 1 hour
Can't make the live date? Register and we'll send you a link to the recording. ​

The threat of protocol amendments adds significant risk to clinical development. Even a single amendment can disrupt clinical research by months — or even years — delaying time-to-market while adding to development costs. Investing time in protocol design upfront can play a critical role in de-risking drug development programs.

This webinar explores the findings of a recent study where 95% of life science executives said that some protocol amendments in their organization could be avoided. Take a deep dive into protocol design and optimization solutions that help keep budgets and timelines on track. Highlights include:

• How protocol amendments add risk to drug development programs, and the top factors driving the need for amendments.
• How developers can manage the risk of amendments throughout protocol development and design.
• Steps leaders can take to secure the support and expertise they need to optimize protocol design — and, consequently, streamline clinical research.

SPEAKERS

Nicole Stansbury
Senior Vice President, Global Clinical Operations
Premier Research
 

Catherine Gatza, Ph.D.
Vice President, Regulatory Strategy
​Premier Research